Situximab is an anti-IL-6 chimeric monoclonal antibody treatment for HIV- and HHV-8-negative patients with multicentric Castleman’s disease (MCD).
Trade name Sylvant.
Siltuximab binds to IL-6, which is overproduced in patients with MCD, andreduces symptoms caused by high-levels of the cytokine.
Iimproves durable tumor and symptomatic responses.
The first therapy for this rare lymphoproliferative disorder.
Improves durable tumor and symptomatic response by 34% compared with no response with placebo plus best supportive care (Wong RSF et pal).
Additionally, 25% of patients treated with siltuximab experienced complete symptom resolution for a minimum of 18 weeks.
At a median 5.1-year follow-up, the median time to treatment failure with siltuximab had not been reached.
The overall response rate was 34% and the durable symptomatic response rate was 57%.
After 13 weeks of therapy, 61% of anemic patients treated experienced an improvement in hemoglobin levels of ≥15 g/L.
Patients treated experienced a sustained reduction in inflammatory markers, such as CRP, ESR, and fibrinogen.
Patients presenting symptoms included fatigue (86%), malaise (61%), night sweats (52%), peripheral sensory neuropathy (38%), anorexia (37%), and pruritus (37%).
Adverse events were fatigue, rash, pruritus, night sweats, upper respiratory tract infection, weight gain, hyperuricemia neutropenia, thrombocytopenia, and hypertension.
,